Pancreatic Cancer

Questions discussed in this category

The patient declined palliative measures only and is motivated to receive treatment

How would you manage a borderline resectable pancreatic cancer s/p induction chemo + chemo-RT who was unable to go to surgery?

Specifically, after chemo and RT to 36.0 Gy/15 fx with stable to slight progression of disease at 6 months, what (if any) regimen of reirradiation wou...

2 Answers available

When treating pancreatic body/tail lesions that result in significant dose spread to the spleen, what is your threshold to offer pneumococcal, hemophilus influenza, and meningococcal vaccines?

2 Answers available

When a patient with pancreatic cancer received neoadjuvant chemo + chemo-RT, how do you manage an in-field, post operative positive margin?

I.e. would you offer additional radiotherapy and if so, what technique and dose would you use?

3 Answers available

Do you always biopsy suspicious liver lesions if you have a biopsy from the pancreatic mass showing PDAC?

Or do you start with systemic therapy and then reassess?

3 Answers available

What is the role of adjuvant radiation in R0 node positive resected pancreatic adenocarcinoma in light of the recently presented RTOG 0848 abstract?

RTOG 0848 presented at ASCO 2024 in abstract form: Abrams et al., Journal of Clinical Oncology 2024 What pathologic factors if any would you use to m...

4 Answers available

What are your top takeaways from ASCO GI 2023?

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice? ...

8 Answers available

How would you treat an elderly patient with biopsy proven extensive non-resectable metastatic pseudopapillary pancreatic tumor?

1 Answer available

Would you offer consolidative full dose chemo-RT for local residual pancreatic disease in a patient with stage IV pancreatic adenocarcinoma with excellent response after induction chemotherapy?

Would you ever consider this approach for an initially polymetastatic patient?

2 Answers available

How long should surgery be delayed in a patient with localized, resectable pancreatic cancer who developed acute pancreatitis following EUS guided biopsy?

And if delayed, should chemotherapy be started?

2 Answers available

Should immunotherapy be added to standard of care neoadjuvant chemotherapy in borderline resectable MSI-H adenocarcinoma of pancreas?

Is there data to support this approach?

2 Answers available

How would you approach a locally advanced ampullary carcinoma with BRCA1 mutation whose Whipple showed complete pathologic response after 5 cycles of neoadjuvant mFOLFIRINOX?

Patient refuses further mFOLFIRINOX but may be open to less aggressive regimens. Is there any role for PARP inhibitors?

1 Answer available

For insurance, how do you justify medical necessity for IMRT to the pancreas in the preoperative, unresectable, and post-operative settings?

1 Answer available

Would you favor starting with pembrolizumab or chemotherapy for a metastatic MSI-high pancreatic ductal adenocarcinoma?

Would your recommendation change in a patient having pain from disease and you wanted a quick response?

1 Answer available

Would you recommend adjuvant chemotherapy for a patient with subcentimeter pancreatic adenocarcinoma incidentally found during a Whipple resection for high risk IPMN?

1 Answer available

In light of the recently published Alliance A021501 trial, what is your approach to incorporating SBRT for the treatment of borderline resectable pancreatic cancer?

A021501 trial: mFOLFIRINOX vs mFOLFIRINOX with hypofractionated radiation (Katz et al., PMID 35834226)

1 Answer available

How would you treat single celiac focus of adenocarcinoma of unknown primary?

Would you consider SBRT as post-chemo consolidation for a patient with a single unresectable focus of metastatic adenocarcinoma at the celiac axis?&nb...

1 Answer available

What is your preferred first line regimen for a patient with BRCA+ metastatic pancreatic cancer with poor performance status?

2 Answers available

What third line treatment do you consider for a patient with metastatic pancreatic cancer with good functional status and no targetable mutations after progression on FOLFIRINOX and gemcitabine/nab-paclitaxel?

3 Answers available